2025
Machine Learning Risk Stratification for Older Breast Cancer Survivors: Clinical Care Implications
Wheeler S, Rotter J, Spees L, Biddell C, Trogdon J, Alfano C, Mayer D, Dinan M, Nekhlyudov L, Birken S. Machine Learning Risk Stratification for Older Breast Cancer Survivors: Clinical Care Implications. Health Services Research 2025, e70005. PMID: 40671264, DOI: 10.1111/1475-6773.70005.Peer-Reviewed Original ResearchBreast cancer survivorsAdverse health outcomesCancer survivorsHealth outcomesCancer-specific deathOlder breast cancer survivorsClinical care implicationsRisk prediction algorithmsAdverse outcomesHigh riskSEER-CAHPSRisk of all-cause deathPrimary careSurvivorship outcomesClinical risk prediction algorithmsCare implicationsClaims dataAll-cause deathCohen's kappaEnd ResultsSurvivorsCancer recurrenceFollow-up periodLow riskCare
2024
Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service Medicare
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply